TACC3: a multi-functional protein promoting cancer cell survival and aggressiveness
ABSTRACT TACC3 is the most oncogenic member of the transforming acidic coiled-coil
domain-containing protein (TACC) family. It is one of the major recruitment factors of distinct …
domain-containing protein (TACC) family. It is one of the major recruitment factors of distinct …
The role of TACC3 in mitotic spindle organization
ZM Ding, CJ Huang, XF Jiao, D Wu, LJ Huo - Cytoskeleton, 2017 - Wiley Online Library
TACC3 regulates spindle organization during mitosis and also regulates centrosome‐
mediated microtubule nucleation by affecting γ‐Tubulin ring complexes. In addition, it …
mediated microtubule nucleation by affecting γ‐Tubulin ring complexes. In addition, it …
E2F1 promotes cell cycle progression by stabilizing spindle fiber in colorectal cancer cells
Z Fang, M Lin, S Chen, H Liu, M Zhu, Y Hu… - Cellular & Molecular …, 2022 - Springer
Background E2F1 is a transcription factor that regulates cell cycle progression. It is highly
expressed in most cancer cells and activates transcription of cell cycle-related kinases …
expressed in most cancer cells and activates transcription of cell cycle-related kinases …
Integrative analysis with expanded DNA methylation data reveals common key regulators and pathways in cancers
The integration of genomic and DNA methylation data has been demonstrated as a powerful
strategy in understanding cancer mechanisms and identifying therapeutic targets. The TCGA …
strategy in understanding cancer mechanisms and identifying therapeutic targets. The TCGA …
A highly potent TACC3 inhibitor as a novel anticancer drug candidate
TACC3, a transforming acidic coiled-coil (TACC) family member, is frequently upregulated in
a broad spectrum of cancers, including breast cancer. It plays critical roles in protecting …
a broad spectrum of cancers, including breast cancer. It plays critical roles in protecting …
PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation
T Tao, X Yang, J Zheng, D Feng, Q Qin, X Shi, Q Wang… - Oncogene, 2017 - nature.com
Renal cell carcinoma (RCC) is one of the most aggressive urologic cancers, however, the
mechanism on supporting RCC carcinogenesis is still not clear. By using gene expression …
mechanism on supporting RCC carcinogenesis is still not clear. By using gene expression …
[HTML][HTML] TACC3 is a prognostic biomarker for kidney renal clear cell carcinoma and correlates with immune cell infiltration and T cell exhaustion
X Fan, B Liu, Z Wang, D He - Aging (Albany NY), 2021 - ncbi.nlm.nih.gov
Growing evidence has demonstrated that transforming acidic coiled-coil protein 3 (TACC3),
a member of the TACC family, may be involved in regulating cell mitosis, transcription, and …
a member of the TACC family, may be involved in regulating cell mitosis, transcription, and …
Developmentally Regulated GTP binding protein 1 (DRG1) controls microtubule dynamics
AK Schellhaus, D Moreno-Andrés, M Chugh… - Scientific Reports, 2017 - nature.com
The mitotic spindle, essential for segregating the sister chromatids into the two evolving
daughter cells, is composed of highly dynamic cytoskeletal filaments, the microtubules. The …
daughter cells, is composed of highly dynamic cytoskeletal filaments, the microtubules. The …
Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer
MJM Magbanua, HS Rugo, L Hauranieh, R Roy… - NPJ breast …, 2018 - nature.com
Detection of disseminated tumor cells (DTCs) in bone marrow is an established negative
prognostic factor. We isolated small pools of (~ 20) EPCAM-positive DTCs from early breast …
prognostic factor. We isolated small pools of (~ 20) EPCAM-positive DTCs from early breast …
Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer
Abstract Trastuzumab emtansine (T-DM1) was the first and one of the most successful
antibody–drug conjugates (ADC) approved for treating refractory HER2-positive breast …
antibody–drug conjugates (ADC) approved for treating refractory HER2-positive breast …